The main difference: how fast they grow and where they start

Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) are two distinct diseases that behave differently, grow at different speeds, and respond to different treatments. The names refer to how the cancer cells look under a microscope, but that visual difference matters because it predicts how the cancer will spread and what will work against it.

NSCLC accounts for roughly 80 to 85 percent of all lung cancers. It grows more slowly than SCLC and often stays in one area longer before spreading to lymph nodes or distant organs. SCLC is less common but more aggressive—it spreads quickly and is usually already advanced by the time it is found. SCLC almost always starts in the central airways of the lungs, while NSCLC can start anywhere in the lung tissue.

Because they behave so differently, a pathologist's diagnosis of which type you have determines which staging system applies, which doctors you see, and which treatments your care team will consider first.

Key Takeaways

  • NSCLC grows slowly and often stays localized; SCLC grows fast and spreads early, so staging and treatment urgency differ significantly.
  • NSCLC staging uses TNM (tumor size, node involvement, metastasis); SCLC uses a simpler two-stage system (limited or extensive disease).
  • NSCLC treatment depends on stage and genetic mutations in the tumor; surgery, radiation, and chemotherapy are common for early stages.
  • SCLC is almost always treated with chemotherapy and radiation together, even when caught early, because surgery rarely helps.
  • Genetic testing of the tumor (not your blood) determines whether targeted drugs or immunotherapy will work for NSCLC.

NSCLC types and where they start in the lung

NSCLC has three main subtypes based on where the cancer cells originate. Adenocarcinoma starts in mucus-producing glands and is the most common type overall; it often develops in the outer edges of the lungs and can occur in people who have never smoked. Squamous cell carcinoma starts in flat cells lining the airways and is more common in current or former smokers; it typically appears in the central part of the lung. Large cell carcinoma is the rarest subtype and grows in cells that look large under the microscope.

The subtype matters because it influences which genetic mutations are most likely present in your tumor, which in turn affects which targeted drugs might work. An adenocarcinoma in a never-smoker, for example, is more likely to carry an EGFR mutation or ALK rearrangement—both of which respond to specific targeted therapies. A squamous cell carcinoma is less likely to have these mutations but may have others.

How NSCLC and SCLC are staged differently

NSCLC uses the TNM staging system, which measures the tumor size (T), whether cancer has spread to lymph nodes (N), and whether it has spread to distant organs (M). This produces stages 0 through 4, with stage 0 being cancer in situ (confined to the surface) and stage 4 meaning cancer has spread to other organs like the brain, bones, or liver. A stage 1 NSCLC tumor is small and has not spread to nodes; a stage 3 tumor may be larger or have spread to nodes in the center of the chest; a stage 4 tumor has spread beyond the lungs.

SCLC uses a much simpler two-stage system. Limited-stage SCLC means the cancer is confined to one lung and the lymph nodes on that side of the chest (and sometimes the center). Extensive-stage SCLC means it has spread to the other lung, to distant lymph nodes, or to organs outside the chest. Because SCLC spreads so quickly, most people are diagnosed with extensive-stage disease.

Staging for both types requires imaging—usually a CT scan of the chest and abdomen, and often a PET scan to look for spread to bones or brain. Your doctor may also order an MRI of the brain if there are symptoms suggesting spread there. Staging determines whether surgery is an option and which chemotherapy or radiation regimens your team will recommend.

Symptoms that may appear before diagnosis

Early-stage lung cancer often causes no symptoms at all, which is why many cases are found by accident on imaging done for another reason. When symptoms do appear, they can include a persistent cough lasting more than three weeks, chest pain that worsens with breathing or coughing, shortness of breath, hoarseness, or coughing up blood. Some people develop recurrent pneumonia in the same spot.

SCLC tends to cause symptoms earlier because it grows faster and often blocks the central airways. You might notice swelling in the face or neck (from a tumor pressing on a vein), weakness or numbness in the legs (from spread to the spine), or confusion or headaches (from spread to the brain). NSCLC may not cause noticeable symptoms until it is more advanced, especially if it starts in the outer edges of the lung.

Symptoms alone do not distinguish between the two types—that requires a biopsy or tissue sample examined under a microscope. If you have symptoms like these, your doctor will order imaging and, if something shows up, will arrange a biopsy to determine the type and subtype.

Treatment for NSCLC: surgery, targeted drugs, and immunotherapy

NSCLC treatment depends on the stage and the genetic makeup of the tumor. For stage 1 and 2 NSCLC, surgery to remove part or all of the affected lung is often the first step, especially if your overall health allows it. After surgery, your doctor may recommend chemotherapy to reduce the risk of recurrence. Some people receive radiation instead of or in addition to surgery if they cannot tolerate an operation.

For stage 3 NSCLC, surgery is less common because the tumor is larger or has spread to lymph nodes in the center of the chest. Treatment usually combines chemotherapy and radiation therapy given together, or chemotherapy alone followed by radiation. Some people receive immunotherapy drugs (checkpoint inhibitors) after chemotherapy and radiation to help the immune system keep fighting remaining cancer cells.

For stage 4 NSCLC, surgery is rarely an option. Treatment focuses on slowing growth and managing symptoms. Your tumor will be tested for specific genetic mutations—EGFR, ALK, ROS1, BRAF, and others. If a mutation is found, a targeted drug that blocks that specific mutation is usually the first choice. If no mutation is found, or if the mutation is not actionable, immunotherapy drugs are often used. Chemotherapy may be added if immunotherapy alone is not working.

The genetic testing is done on tumor tissue, not on your blood. A pathologist examines the biopsy sample or surgical specimen and runs tests to look for mutations. This testing takes one to two weeks and is essential for choosing the right drug.

Treatment for SCLC: chemotherapy and radiation as the standard approach

SCLC is treated very differently from NSCLC because it is so aggressive and because surgery rarely helps—by the time SCLC is found, it has usually already spread beyond the lung. The standard treatment for limited-stage SCLC is chemotherapy and radiation therapy given at the same time. The chemotherapy regimen most commonly used is etoposide plus cisplatin or carboplatin, given in cycles over several months. Radiation targets the lung and the lymph nodes in the center of the chest.

For extensive-stage SCLC, chemotherapy is the main treatment, often the same etoposide-based regimen. Radiation may be added to the chest if there is a large tumor there, or to the brain if imaging shows spread. Immunotherapy drugs are sometimes added to chemotherapy for extensive-stage disease, though this is still being studied in clinical trials.

SCLC does not have the same genetic mutations that NSCLC does, so targeted drugs are not used. Immunotherapy is less effective in SCLC than in NSCLC, which is one reason why chemotherapy remains the backbone of treatment. If the cancer comes back after initial treatment, second-line chemotherapy with different drugs may be offered, but options are more limited than they are for NSCLC.

What happens after initial treatment: surveillance and managing recurrence

After you complete treatment for either type of lung cancer, your care team will schedule follow-up imaging—usually CT scans of the chest every three months for the first year or two, then less frequently if no recurrence is found. These scans look for signs that cancer has returned. You will also see your oncologist regularly to discuss any new symptoms and to monitor for side effects from treatment.

If cancer recurs, treatment options depend on how long it has been since your initial treatment, what type of cancer you have, and your overall health. For NSCLC, if a new mutation has emerged or if the tumor has changed, additional genetic testing may be done. For SCLC, recurrence is unfortunately common, and second-line options are more limited.

Palliative care—treatment focused on managing pain, shortness of breath, and other symptoms—can be started at any point, even while you are receiving chemotherapy or radiation. Palliative care is not the same as hospice; it works alongside curative treatment to improve quality of life.

Frequently Asked Questions

Can NSCLC turn into SCLC or vice versa?

NSCLC and SCLC are separate diseases that do not transform into each other. However, a small number of tumors have both NSCLC and SCLC components mixed together; these are called combined-type cancers and are treated more like SCLC. A biopsy at diagnosis determines which type you have.

Why is genetic testing only done on the tumor, not on my blood?

The mutations that matter for lung cancer treatment are in the cancer cells themselves, not in your normal cells. A blood test cannot reliably detect these tumor-specific mutations. Tissue from a biopsy or surgery is examined under a microscope and tested for mutations that predict which drugs will work.

If I had NSCLC stage 1 and had surgery, do I need chemotherapy?

Not always. For very small stage 1 tumors with no spread to lymph nodes, surgery alone may be enough. For larger stage 1 tumors or those with any lymph node involvement, chemotherapy after surgery reduces the risk of recurrence. Your oncologist will discuss this based on the exact size and characteristics of your tumor.

Is SCLC always fatal?

SCLC is serious and aggressive, but people do survive it, especially when caught at limited stage and treated with chemotherapy and radiation. Survival varies widely depending on stage at diagnosis, overall health, and how well the cancer responds to treatment. Your oncologist can discuss prognosis based on your specific situation.

What if I cannot tolerate chemotherapy side effects?

Tell your oncologist immediately. Dose reductions, changes to the chemotherapy regimen, or switching to different drugs may be possible. For NSCLC, targeted drugs or immunotherapy might be options instead of chemotherapy. For SCLC, options are more limited, but your team can work with you on managing side effects or adjusting the plan.